Palatin Technologies, Inc.
Index- P/E- EPS (ttm)-3.90 Insider Own10.10% Shs Outstand10.35M Perf Week-4.98%
Market Cap39.34M Forward P/E- EPS next Y-1.69 Insider Trans0.00% Shs Float9.88M Perf Month-16.98%
Income-37.30M PEG- EPS next Q-0.70 Inst Own8.20% Short Float / Ratio1.88% / 2.47 Perf Quarter-12.83%
Sales2.20M P/S17.88 EPS this Y-6.90% Inst Trans17.02% Short Interest0.19M Perf Half Y-56.65%
Book/sh-0.68 P/B- EPS next Y33.50% ROA-93.00% Target Price43.00 Perf Year-71.07%
Cash/sh2.16 P/C1.86 EPS next 5Y- ROE-257.50% 52W Range3.78 - 17.10 Perf YTD-68.65%
Dividend- P/FCF- EPS past 5Y-15.90% ROI- 52W High-76.55% Beta0.76
Dividend %- Quick Ratio1.60 Sales past 5Y-49.50% Gross Margin88.50% 52W Low6.08% ATR0.36
Employees33 Current Ratio1.70 Sales Q/Q350.00% Oper. Margin- RSI (14)40.23 Volatility6.81% 8.17%
OptionableYes Debt/Eq- EPS Q/Q-14.80% Profit Margin- Rel Volume0.36 Prev Close4.15
ShortableYes LT Debt/Eq- EarningsNov 14 BMO Payout- Avg Volume75.02K Price4.01
Recom1.30 SMA20-7.14% SMA50-20.66% SMA200-47.13% Volume27,276 Change-3.37%
Jun-05-15Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15Reiterated ROTH Capital Buy $6 → $4
May-23-12Initiated Noble Financial Buy
Jan-23-07Initiated Next Generation Buy $5
Nov-14-22 08:55AM
Nov-10-22 08:55AM
Nov-09-22 06:45PM
07:25PM Loading…
Nov-08-22 07:25PM
Nov-07-22 05:15PM
Oct-31-22 09:30AM
Oct-27-22 07:05AM
Oct-24-22 05:32PM
Oct-20-22 07:30AM
Oct-17-22 07:30AM
Oct-13-22 07:30AM
Sep-29-22 03:45PM
11:00AM Loading…
Sep-22-22 11:00AM
Sep-19-22 04:15PM
Sep-08-22 07:30AM
Sep-02-22 10:28AM
Aug-19-22 07:30AM
Aug-16-22 07:30AM
Jul-26-22 07:30AM
Jul-13-22 10:53AM
May-17-22 08:45AM
May-16-22 07:15AM
May-12-22 08:15AM
09:02AM Loading…
May-11-22 09:02AM
May-10-22 08:45AM
May-09-22 05:15PM
May-05-22 06:05PM
May-02-22 01:02PM
Apr-21-22 07:30AM
Apr-13-22 08:24AM
Mar-03-22 07:30AM
Feb-15-22 07:30AM
Feb-14-22 08:15PM
Feb-10-22 05:25PM
Feb-09-22 03:01PM
Feb-08-22 02:38PM
Jan-21-22 07:30AM
Jan-07-22 10:59AM
Dec-29-21 10:18AM
Dec-28-21 07:30AM
Dec-06-21 03:55PM
Nov-30-21 07:30AM
Nov-24-21 11:20AM
Nov-15-21 07:30AM
Nov-10-21 04:30PM
Oct-22-21 07:30AM
Sep-29-21 07:30AM
Sep-27-21 07:30AM
Sep-24-21 07:30AM
Sep-15-21 07:30AM
Sep-13-21 07:00AM
Jul-22-21 05:28PM
Jul-08-21 04:15PM
Jun-29-21 07:30AM
Jun-28-21 07:30AM
Jun-10-21 07:30AM
May-17-21 09:15AM
May-14-21 07:30AM
May-13-21 07:30AM
May-04-21 07:30AM
Apr-20-21 07:30AM
Mar-11-21 08:17AM
Mar-05-21 07:30AM
Feb-17-21 09:15AM
Feb-12-21 07:30AM
Feb-11-21 09:59AM
Feb-10-21 08:01AM
Feb-05-21 09:47AM
Feb-04-21 11:30AM
Dec-22-20 01:17PM
Dec-15-20 07:00AM
Nov-29-20 12:13PM
Nov-19-20 11:11AM
Nov-17-20 09:15AM
Nov-12-20 07:30AM
Sep-28-20 09:00AM
Sep-24-20 04:00PM
Sep-10-20 05:47PM
Aug-13-20 04:12PM
Jul-14-20 01:19PM
Jul-08-20 07:30AM
Jun-29-20 07:30AM
Jun-23-20 04:54PM
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.